With an emphasis on research and how well patients are living, the Pulmonary Fibrosis Foundation’s (PFF) PFF Summit 2021 is set to take place virtually Nov. 8–13. The global biennial pulmonary fibrosis (PF) conference, which is sponsored in part by Boehringer Ingelheim, will offer live, interactive educational…
Alterations in the extracellular matrix — the network of molecules that surrounds and supports cells — and cell aging, a process of called senescence, both contribute to tissue scarring in idiopathic pulmonary fibrosis (IPF), according to a recent study. Yet, matrix changes do not lead to senescence, implying that…
Gefapixant (MK-7264), an investigational cough suppressant, was safe and well-tolerated by patients with idiopathic pulmonary fibrosis (IPF), but did not significantly reduce chronic coughing, according to data from a Phase 2 clinical trial. Results from this trial were shared in the study, “Treatment of Persistent Cough in Subjects…
Four months of treatment with Tyvaso (inhaled treprostinil) significantly improved lung function in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a post-hoc analysis of data from the Phase 2/3 INCREASE clinical trial. PH-ILD comprises a group of conditions characterized by significant lung scarring (fibrosis), including…
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases within the next decade. A leader in the field of genetic diagnostics, Centogene used the June 22 event to present its strategic priorities, outlining its plans to speed the discovery…
Hyperbaric oxygen therapy can counteract some of the key features of pulmonary fibrosis (PF) in mice and human lung cells, a recent study reveals. The findings suggest this treatment, involving the delivery of pure oxygen in a high pressure chamber, should be investigated more closely as a potential PF…
Investigators have discovered a new biomarker in a molecule called cutaneous T-cell-attracting chemokine, or CTACK, that may help determine the course of idiopathic pulmonary fibrosis (IPF). The discovery was detailed in the study, “Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary…
Pieris Pharmaceuticals plans to start clinical development of PRS-220 in 2022 for idiopathic pulmonary fibrosis (IPF) — and also will advance the investigative, inhaled therapy for “long COVID” PF, or post-COVID-19 pulmonary fibrosis, the company said. The clinical development of PRS-220 for long COVID pulmonary fibrosis will be…
The acid reflux medication esopremazole, commonly used to ease symptoms of gastroesophageal reflux disease (GERD), may be able to reduce lung scarring and inflammation in idiopathic pulmonary fibrosis (IPF), a recent study suggests. “Esomeprazole favorably regulates a network of genes involved in lung fibrosis [scarring],” according…
A computer analysis identified a tiny RNA molecule, or microRNA, as a potential therapeutic target to halt the progression of idiopathic pulmonary fibrosis (IPF), which was confirmed later in cell-based tests. Researchers now plan to use these results to develop new RNA-based therapeutics or small molecules with the potential…
Get regular updates to your inbox.
